Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in:

Open Access 01-12-2024 | Bladder Cancer | Research

Nucleolar protein 3 promotes proliferation of bladder cancer cells through the PI3K-Akt pathway

Authors: Linfeng Wu, Kunyao Zhu, Yan Sun, Tinghao Li, Junlong Zhu, Hang Tong, Xiaoyu Zhang, Junrui Chen, Hubin Yin, Weiyang He

Published in: World Journal of Surgical Oncology | Issue 1/2024

Login to get access

Abstract

Nucleolar protein 3 (NOL3), as a markedly increased protein across a range of tumors, has been well acknowledged that plays an anti-apoptotic role in malignancies, while some novel impacts of NOL3 on metastasis and chemoresistance are demonstrated recently. In this study, we uncover another role of NOL3 on promoting proliferation in bladder cancer (BLCA). The reduction of NOL3 significantly inhibited cell proliferation, and we detected the stable cell cycle arrest after knockdown of NOL3 in two-type BLCA cell lines. Mechanistically, we present the first evidence that the PI3K/Akt pathway was considerably inhibited with the decrease of NOL3 in BLCA cell lines. In addition, LY294002, a PI3K inhibitor, rescued NOL3 overexpression-mediated activation of the PI3K/Akt axis and the depression of proliferation in BLCA cell lines. In conclusion, our study suggests that NOL3 is upregulated in BLCA cells and promotes proliferation via the PI3K/Akt pathway, indicating that NOL3 may be a potential therapeutic target for BLCA.
Appendix
Available only for authorised users
Literature
1.
Lenis A T, Lec P M, Chamie K. Bladder Cancer: a review [J]. Jama-Journal Am Med Association. 2020;324(19):1980–91.CrossRef
2.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. Ca-a Cancer J Clin. 2021;71(3):209–49.CrossRef
3.
Ding X, Jin Y, Shi X, et al. TDO2 promotes bladder cancer progression via AhR-mediated SPARC/FILIP1L signaling [J]. Biochem Pharmacol. 2024;223:116172.CrossRefPubMed
4.
Koseki T, Inohara N, Chen S, et al. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases [J]. Proc Natl Acad Sci USA. 1998;95(9):5156–60.CrossRefPubMedPubMedCentral
5.
Hong YM, Jo D G, Lee JY, et al. Down-regulation of ARC contributes to vulnerability of hippocampal neurons to ischemia/hypoxia [J]. FEBS Lett. 2003;543(1–3):170–3.CrossRefPubMed
6.
Lin Z W Ekhterae D, Lundberg M S, et al. ARC inhibits cytochrome < i > c release from mitochondria and protects against hypoxia-induced apoptosis in heart-derived H9c2 cells [J]. Circul Res. 1999;85(12):E70–7.
7.
Nam YJ, Mani K, Ashton A W, et al. Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions [J]. Mol Cell. 2021;81(3):638.CrossRefPubMed
8.
Zaiman AL, Damico R, Thoms-Chesley A, et al. A critical role for the protein apoptosis Repressor with Caspase Recruitment Domain in Hypoxia-Induced Pulmonary hypertension [J]. Circulation. 2011;124(23):2533–42.CrossRefPubMedPubMedCentral
9.
Liu M X, Yu T, Li M Y, et al. Apoptosis repressor with caspase recruitment domain promotes cell proliferation and phenotypic modulation through 14-3-3ε/YAP signaling in vascular smooth muscle cells [J]. J Mol Cell Cardiol. 2020;147:35–48.CrossRef
10.
Li T D, Huang M W, Sun N et al. Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from < i > SNHG1 upregulation [J]. J Experimental Clin Cancer Res, 2024, 43(1).
11.
Xie B, Lin J T, Chen X W et al. CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer [J]. Mol Cancer, 2023, 22(1).
12.
Rezaei S, Nikpanjeh N, Rezaee A et al. PI3K/Akt signaling in urological cancers: tumorigenesis function, therapeutic potential, and therapy response regulation [J]. Eur J Pharmacol, 2023, 955.
13.
Stanley R F, Piszczatowski R T, Bartholdy B, et al. A myeloid tumor suppressor role for < i > NOL3 [J]. J Exp Med. 2017;214(3):753–71.CrossRefPubMed
14.
Tong H, Li T H, Gao S et al. An epithelial-mesenchymal transition-related long noncoding RNA signature correlates with the prognosis and progression in patients with bladder cancer [J]. Biosci Rep, 2021, 41(1).
15.
Liu K, Lan D F, Li C Y et al. A double-edged sword: role of apoptosis repressor with caspase recruitment domain (ARC) in tumorigenesis and ischaemia/reperfusion (I/R) injury [J]. Apoptosis, 2023, 28(3–4): 313 – 25.
16.
Hunter A L, Zhang J C, Chen S C, et al. Apoptosis repressor with caspase recruitment domain (ARC) inhibits myogenic differentiation [J]. FEBS Lett. 2007;581(5):879–84.CrossRefPubMed
17.
Templin A T, Samarasekera T, Meier D T, et al. Apoptosis Repressor with Caspase Recruitment Domain ameliorates amyloid-Induced β-Cell apoptosis and JNK pathway activation [J]. Diabetes. 2017;66(10):2636–45.CrossRefPubMed
18.
Ke YJ, Yan H H, Chen L W, et al. Apoptosis repressor with caspase recruitment domain deficiency accelerates ischemia/reperfusion (I/R)-induced acute kidney injury by suppressing inflammation and apoptosis: the role of AKT/mTOR signaling [J]. Biomedicine & Pharmacotherapy; 2019. p. 112.
19.
Carter B Z, Mak P Y, Wang X M, et al. An ARC-Regulated IL1β/Cox-2/PGE2/β-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and confers Drug Resistance in AML [J]. Cancer Res. 2019;79(6):1165–77.CrossRefPubMedPubMedCentral
20.
He QL, Li Z Q Yin JB et al. Prognostic significance of autophagy-relevant gene markers in Colorectal Cancer [J]. Front Oncol, 2021, 11.
21.
Li Q, Yang J, Zhang J, et al. Inhibition of microRNA-327 ameliorates ischemia/reperfusion injury-induced cardiomyocytes apoptosis through targeting apoptosis repressor with caspase recruitment domain [J]. J Cell Physiol. 2020;235(4):3753–67.CrossRefPubMed
22.
Li Y Z, Ge X L, Liu X, H. The cardioprotective effect of postconditioning is mediated by ARC through inhibiting mitochondrial apoptotic pathway [J]. Apoptosis. 2009;14(2):164–72.CrossRef
23.
Roser C, Tóth C, Renner M et al. Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin [J]. Cell Communication Signal, 2021, 19(1).
24.
Zhang F Y, Yu S C, Wu P J, et al. Discovery and construction of prognostic model for clear cell renal cell carcinoma based on single-cell and bulk transcriptome analysis [J]. Translational Androl Urol. 2021;10(9):3540–.CrossRef
25.
Zhang J, Zheng X X, Wang P Y, et al. Role of apoptosis repressor with caspase recruitment domain (ARC) in cell death and cardiovascular disease [J]. Apoptosis. 2021;26(1–2):24–37.CrossRefPubMed
26.
Su H, Peng C, Liu Y. Regulation of ferroptosis by PI3K/Akt signaling pathway: a promising therapeutic axis in cancer [J]. Front Cell Dev Biology, 2024, 12.
27.
Zhou K L, Wu C L, Cheng W J, et al. Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-AKT signaling pathway-mediated keratin 14 degradation [J]. Volume 15. Cell Death & Disease; 2024. 4.
28.
Li JK, Jiang X L, Zhang Z, et al. Isoalantolactone exerts anti-melanoma effects via inhibiting PI3K/AKT/mTOR and STAT3 signaling in cell and mouse models [J]. Phytotherapy Research; 2024.
29.
Liu H, Zhang J H, Zhao Y J et al. CD93 regulates breast cancer growth and vasculogenic mimicry through the PI3K/AKT/SP2 signaling pathway activated by integrin β1 [J]. J Biochem Mol Toxicol, 2024, 38(4).
30.
Peng Y, Wang Y Y, Zhou C et al. PI3K/Akt/mTOR pathway and its role in Cancer therapeutics: are we making Headway? [J]. Front Oncol, 2022, 12.
31.
Leiphrakpam PD. Are C. PI3K/Akt/mTOR signaling pathway as a target for Colorectal Cancer treatment [J]. Int J Mol Sci, 2024, 25(6).
32.
Metadata
Title
Nucleolar protein 3 promotes proliferation of bladder cancer cells through the PI3K-Akt pathway
Authors
Linfeng Wu
Kunyao Zhu
Yan Sun
Tinghao Li
Junlong Zhu
Hang Tong
Xiaoyu Zhang
Junrui Chen
Hubin Yin
Weiyang He
Publication date
01-12-2024
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2024
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-024-03600-5

Other articles of this Issue 1/2024

Inactivation and replantation of the knee joint: an infeasible surgical method

BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population

Splenic cyst deroofing complicated with B lymphoma

Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: an updated meta-analysis and meta-regression of observational studies

Prognostic factors for invasive mucinous adenocarcinoma of the lung: systematic review and meta-analysis

Symptom burden and clusters during chemotherapy in patients with lung cancer

SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

  • Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now
Image Credits